William Lawrence and Blanche Hughes Foundation Report issue

Foundation Phase 1

Organization Overview

First Clinical Trial
2014
NCT02091245
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (1)

selinexor (Xpovio) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blast Crisis (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1